Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) (IMMVF) - Net Assets
Latest net assets as of December 2025: $64.57 Million USD
Based on the latest financial reports, Immunovia AB (publ) (IMMVF) has net assets worth $64.57 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($87.99 Million) and total liabilities ($23.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.57 Million |
| % of Total Assets | 73.39% |
| Annual Growth Rate | 23.89% |
| 5-Year Change | -85.12% |
| 10-Year Change | -76.66% |
| Growth Volatility | 213.2 |
Immunovia AB (publ) - Net Assets Trend (2013–2025)
This chart illustrates how Immunovia AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immunovia AB (publ) (2013–2025)
The table below shows the annual net assets of Immunovia AB (publ) from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $64.57 Million | +454.32% |
| 2024-12-31 | $11.65 Million | -82.61% |
| 2023-12-31 | $66.99 Million | -72.52% |
| 2022-12-31 | $243.80 Million | -43.81% |
| 2021-12-31 | $433.90 Million | -27.61% |
| 2020-12-31 | $599.40 Million | +67.62% |
| 2019-12-31 | $357.61 Million | -22.59% |
| 2018-12-31 | $461.95 Million | +95.09% |
| 2017-12-31 | $236.80 Million | -14.40% |
| 2016-12-31 | $276.63 Million | +230.11% |
| 2015-12-31 | $83.80 Million | +134.45% |
| 2014-12-31 | $35.74 Million | +623.64% |
| 2013-12-31 | $4.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunovia AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 127741033400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.13 Million | 31.17% |
| Other Comprehensive Income | $16.55 Million | 25.63% |
| Other Components | $1.31 Billion | 2022.04% |
| Total Equity | $64.57 Million | 100.00% |
Immunovia AB (publ) Competitors by Market Cap
The table below lists competitors of Immunovia AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baikowski SASU
PA:ALBKK
|
$16.62 Million |
|
WVS Financial Corp
OTCQX:WVFC
|
$16.63 Million |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
$16.63 Million |
|
FORCS Co.Ltd
KQ:189690
|
$16.63 Million |
|
Autech Corporation
KQ:067170
|
$16.62 Million |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
$16.62 Million |
|
CItech Co Ltd
KO:004920
|
$16.60 Million |
|
Aura Investments Ltd
TA:AURA
|
$16.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunovia AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,649,000 to 64,572,610, a change of 52,923,610 (454.3%).
- Net loss of 145,548,968 reduced equity.
- New share issuances of 138,022,000 increased equity.
- Other comprehensive income increased equity by 60,684,374.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-145.55 Million | -225.4% |
| Share Issuances | $138.02 Million | +213.75% |
| Other Comprehensive Income | $60.68 Million | +93.98% |
| Other Changes | $-233.80K | -0.36% |
| Total Change | $- | 454.32% |
Book Value vs Market Value Analysis
This analysis compares Immunovia AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.19x to 0.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.40 | $0.07 | x |
| 2014-12-31 | $2.86 | $0.07 | x |
| 2015-12-31 | $6.81 | $0.07 | x |
| 2016-12-31 | $17.13 | $0.07 | x |
| 2017-12-31 | $12.98 | $0.07 | x |
| 2018-12-31 | $23.12 | $0.07 | x |
| 2019-12-31 | $16.96 | $0.07 | x |
| 2020-12-31 | $26.07 | $0.07 | x |
| 2021-12-31 | $17.79 | $0.07 | x |
| 2022-12-31 | $10.00 | $0.07 | x |
| 2023-12-31 | $1.72 | $0.07 | x |
| 2024-12-31 | $0.14 | $0.07 | x |
| 2025-12-31 | $0.19 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunovia AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -225.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21301.48%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.36x
- Recent ROE (-225.40%) is below the historical average (-124.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -32.32% | -135.45% | 0.16x | 1.51x | $-2.09 Million |
| 2014 | -24.79% | -2466.58% | 0.01x | 1.09x | $-12.43 Million |
| 2015 | -8.81% | -3598.41% | 0.00x | 1.09x | $-15.76 Million |
| 2016 | -5.32% | -8304.88% | 0.00x | 1.02x | $-42.39 Million |
| 2017 | -19.10% | -30364.72% | 0.00x | 1.06x | $-68.91 Million |
| 2018 | -18.73% | -25987.69% | 0.00x | 1.03x | $-132.73 Million |
| 2019 | -32.02% | -32168.82% | 0.00x | 1.17x | $-150.28 Million |
| 2020 | -24.36% | -40340.61% | 0.00x | 1.10x | $-205.97 Million |
| 2021 | -35.94% | -18479.38% | 0.00x | 1.14x | $-199.36 Million |
| 2022 | -68.95% | -14680.52% | 0.00x | 1.23x | $-192.47 Million |
| 2023 | -461.91% | -19646.92% | 0.02x | 1.47x | $-316.14 Million |
| 2024 | -657.06% | -8221.37% | 0.03x | 2.84x | $-77.71 Million |
| 2025 | -225.40% | -21301.48% | 0.01x | 1.36x | $-152.01 Million |
Industry Comparison
This section compares Immunovia AB (publ)'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunovia AB (publ) (IMMVF) | $64.57 Million | -32.32% | 0.36x | $16.62 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |